RHBC
PVCT

R.H. Bluestein & Co’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

R.H. Bluestein & Co’s Portfolio PVCT Stock Details PVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-10,000
Closed -$9K – 387
2014
Q2 		$9K Buy
+10,000
New +$12K ﹤0.01% 356

Other funds holding PVCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
PCM
Princeton Capital Management Red Bank, New Jersey $367M AUM 45.24% 1-Year Est. Return

R.H. Bluestein & Co's PVCT Position: Q3 2014 in Review

R.H. Bluestein & Co sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q3 2014, closing a stake of 10,000 shares — an estimated $9K sold.

R.H. Bluestein & Co first reported a position in PVCT in Q2 2014 and held it in 1 quarter. The position peaked at $9K in Q2 2014. 30 funds tracked by Wall St. Rank hold PVCT as of Q3 2014.

  • R.H. Bluestein & Co reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q3 2014 after selling out during the quarter.
  • R.H. Bluestein & Co sold 10,000 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q3 2014, an estimated $9K.
  • R.H. Bluestein & Co first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q2 2014 and held it in 1 quarter.
  • R.H. Bluestein & Co's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $9K in Q2 2014.
  • 30 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q3 2014.

Based on R.H. Bluestein & Co's 13F filing for Q3 2014, filed 12 Nov 2014.